期刊
CURRENT VASCULAR PHARMACOLOGY
卷 20, 期 5, 页码 409-428出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1570161120666220819163025
关键词
Ischemic preconditioning; cardiac pharmacology; ischemia-reperfusion injury; heart disease; signaling pathways; cardioprotection
Ischemic preconditioning is a phenomenon that increases tissue or organ's tolerance to ischemia by applying brief cycles of ischemia/reperfusion. This review discusses the effects of various medications on myocardial ischemic preconditioning, which has potential therapeutic implications.
Ischemic preconditioning (IP) is an innate phenomenon, triggered by brief, non-lethal cycles of ischemia/reperfusion applied to a tissue or organ that confers tolerance to a subsequent more prolonged ischemic event. Once started, it can reduce the severity of myocardial ischemia associated with some clinical situations, such as percutaneous coronary intervention (PCI) and intermittent aortic clamping during coronary artery bypass graft surgery (CABG). Although the mechanisms underlying IP have not been completely elucidated, several studies have shown that this phenomenon involves the participation of cell triggers, intracellular signaling pathways, and end-effectors. Understanding this mechanism enables the development of preconditioning mimetic agents. It is known that a range of medications that activate the signaling cascades at different cellular levels can interfere with both the stimulation and the blockade of IP. Investigations of signaling pathways underlying ischemic conditioning have identified a number of therapeutic targets for pharmacological manipulation. This review aims to present and discuss the effects of several medications on myocardial IP.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据